Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 09 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding the in-licensing of a critical drug for chronic kidney disease patients from Pharmacosmos A/S of Denmark. The drug, MonoFerric, is an iron isomaltoside injection indicated for treating iron deficiency when oral preparations are ineffective. This acquisition allows Zydus to market MonoFerric in India and Nepal, enhancing their portfolio in the nephrology segment. The press release emphasizes the importance of addressing iron deficiency, particularly in chronic kidney disease patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases